Throughout my career I have been passionate and championed the use of mathematical models and analysis for pharmaceutical process development. I have developed innovative, effective strategies to maximize model deployment and increase productivity. With a doctorate in structure and catalytic activity of novel solid acids, an extensive research and publication background, and hands-on knowledge of the pharmaceutical industry, I have contributed to technology that facilitates the production, deployment, and consumption of modelling, ultimately influencing and improving business decisions.
In addition to my most recent role at Bristol Myers Squibb R&D, I work with other pharmaceutical companies in the pre-competitive space, developing platforms to increase software access for model developers and enable collaboration for model development and publication. I am passionate about constructing and enhancing pharmaceutical processes, particularly mathematical models for process and material characterization.
By deploying tools for cloud-based reproducible research, I have championed the introduction of multiple software and platforms, including:
- Leading software (Stan) for uncertainty quantification with Bayesian inference
- Strategic deployment of computational platforms (EASA and DOMINO) to enable modeling distribution
- As part of the Enabling Technologies Consortium, currently working on the development of a cloud platform for model development and deployment in any software.
The pharma industry is fast-paced and always changing, and businesses must keep up with cutting-edge modeling tools. As an experienced and analytical professional, I am eager to continue honing my skills as a data scientist and demonstrate how my keen eye for innovation can improve overall performance.